Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to -$85.3 million.

  • Viking Therapeutics' Free Cash Flow fell 17353.2% to -$85.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$278.7 million, marking a year-over-year decrease of 21744.5%. This contributed to the annual value of -$278.7 million for FY2025, which is 21744.5% down from last year.
  • Latest data reveals that Viking Therapeutics reported Free Cash Flow of -$85.3 million as of Q4 2025, which was down 17353.2% from -$94.0 million recorded in Q3 2025.
  • Viking Therapeutics' 5-year Free Cash Flow high stood at -$6.1 million for Q1 2024, and its period low was -$94.0 million during Q3 2025.
  • Its 5-year average for Free Cash Flow is -$26.8 million, with a median of -$15.6 million in 2022.
  • As far as peak fluctuations go, Viking Therapeutics' Free Cash Flow skyrocketed by 7510.86% in 2024, and later plummeted by 75313.01% in 2025.
  • Viking Therapeutics' Free Cash Flow (Quarter) stood at -$12.4 million in 2021, then increased by 11.53% to -$10.9 million in 2022, then plummeted by 61.45% to -$17.6 million in 2023, then tumbled by 76.76% to -$31.2 million in 2024, then plummeted by 173.53% to -$85.3 million in 2025.
  • Its last three reported values are -$85.3 million in Q4 2025, -$94.0 million for Q3 2025, and -$47.1 million during Q2 2025.